Doxorubicin and taxane combination regimens for metastatic breast cancer: Focus on cardiac effects
References (34)
- et al.
Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: Phase I results
Ann Oncol
(1999) - et al.
Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxic
Ann Oncol
(1996) - et al.
Dose-finding study of Taxotere and doxorubicin in first-line treatment of patients with metastatic breast cancer
Ann Oncol
(1999) - et al.
Chemotherapy and survival in advanced breast cancer: The inclusion of doxorubicin in Cooper type regimens
Br J Cancer
(1993) - et al.
Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer
J Natl Cancer Inst
(1991) - et al.
Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer
J Clin Oncol
(1996) - et al.
Phase II trial of docetaxel: A new highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer
J Clin Oncol
(1995) - et al.
Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer
J Clin Oncol
(1995) - et al.
Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: A European Organization for Research and Treatment of Cancer randomized study with crossover
J Clin Oncol
(2000) - et al.
Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer
J Clin Oncol
(1999)
Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing therapy
J Clin Oncol
A phase III study of docetaxel vs. doxorubicin in patients with metastatic breast cancer who have failed an alkylating containing regime
J Clin Oncol
Doxorubicin-induced cardiomyopathy
N Engl J Med
Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion
Ann Intern Med
Risk factors for doxorubicin-induced congestive heart failure
Ann Intern Med
Sequence of taxol and cisplatin: A phase 1 and pharmacologic study
J Clin Oncol
Sequence dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer
J Clin Oncol
Cited by (27)
Investigation of the antitumor activity and toxicity of long-circulating and fusogenic liposomes co-encapsulating paclitaxel and doxorubicin in a murine breast cancer animal model
2019, Biomedicine and PharmacotherapyCitation Excerpt :No signs of cardiac toxicity were observed for animals in any other groups of treatment. These findings show that the co-encapsulation of PTX and DXR in liposomes leads to a reduction in the toxicity of the combination, enabling the co-administration of PTX and DXR and suggesting that it is more effective than the administration of DXR and PTX treatments separately at different time intervals [55,56]. The co-administration of these agents is nowadays hampered due to the pharmacokinetic interference of PTX in DXR elimination, which leads to enhanced plasma concentrations of DXR and its metabolite, doxorubicinol, also known to be highly cardiotoxic [57,58].
MYC Amplification as a Predictive Factor of Complete Pathologic Response to Docetaxel-based Neoadjuvant Chemotherapy for Breast Cancer
2017, Clinical Breast CancerCitation Excerpt :The taxanes have substantial activity against breast cancer, even after failed treatment with anthracyclines.7 However, the treatment with this regimen presents several adverse effects, including nausea, vomiting, low white blood cell counts, cardiotoxicity, fever, diarrhea, and peripheral neuropathy.8,9 Currently, there are no clinically useful predictive markers to identify patients who are likely to respond to taxanes.10
Current directions for COX-2 inhibition in breast cancer
2005, Biomedicine and PharmacotherapyDrug-drug interactions in oncology: Why are they important and can they be minimized?
2005, Critical Reviews in Oncology/HematologyMyocardial Infarction Induced by Paclitaxel [3]
2003, Therapie
- 1
Dr Valero has received research support and honoraria from Aventis and Bristol-Myers Squibb.